Management of hepatitis C/HIV coinfection

Current Opinion in Infectious Diseases

Volumn 19, Issue 1, 2006, Pages 8-13

  Rockstroh, Jürgen K ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b Department of Medicine I ^*  (Germany)

Author keywords

Hepatitis C; Hepatitis C virus genotype; HIV; Pegylated interferon; Ribavirin

Indexed keywords

ANTIRETROVIRUS AGENT; CYCLOSPORIN A; DIDANOSINE; IMMUNOSUPPRESSIVE AGENT; PEGINTERFERON; RIBAVIRIN; STAVUDINE; TACROLIMUS; ZALCITABINE; ZIDOVUDINE;

ANEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LACTIC ACIDOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MITOCHONDRIAL TOXICITY; NONHUMAN; PANCREATITIS; REVIEW; TIME SERIES ANALYSIS; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 29744437050     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000200294.22661.e0     Document Type: Review

References (41)

1. Rockstroh JK, Mocroft A, Soriano V, et al. for the EuroSIDA study group. Influence of hepatitis C on HIV disease progression and response to antiretroviral therapy. J Infect Dis 2005; 192:992-1002. This paper is among the first to describe the epidemiological situation of HIV/HCV coinfection in various regions from Europe. Moreover, it tries to answer the question of how far hepatitis C coinfection has an impact on the course of HIV in almost 6000 patients and to discuss the discrepancies that exist in the literature.
2. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593-601. This paper is among the first to describe the epidemiological situation of HIV/ hepatitis B virus coinfection in various regions of Europe. Moreover, it demonstrates that chronic hepatitis B virus infection significantly increased liver-related mortality in HIV-1-infected patients but did not impact on progression to AIDS or on viral and immunological responses to HAART.
3. Rockstroh JK, Spengler U, Sudhop T, et al. Immunosuppression may lead to progression of hepatitis C virus associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996; 91:2563-2568.
4. Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17:1803-1809.
5. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection. Lancet 2003; 362:1708-1713.
6. Chung RT, Andersen J, Volberding P, et al. AIDS Clinical Trials Group A5071 Study Team. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459.
7. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450. Randomized clinical trial comparing the efficacy and safety of PegIFN alfa-2a plus either ribavirin or placebo with those of interferon alfa-2a plus ribavirin for the treatment of chronic HCV infection in patients who were also infected with HIV in a total of 868 persons. This is the largest clinical trial to date in the field of coinfection, with many important findings.
8. Carrat F, Bani-Sadr F, Pol S, et al. ANRS HCO2 RIBAVIC Study Team. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-2848. Study evaluating the safety and efficacy of PegIFN alfa-2b plus ribavirin compared with standard interferon alfa-2b plus ribavirin in 412 HIV/HCV-coinfected patients. It is an important trial which offers much information on risk factors for adverse events and clearly has led to the contraindication for using didanosine and ribavirin concomitantly.
9. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV coinfected patients. AIDS 2004; 18:F27-F34.
10. Cargnel A, Angeli E, Mainini A, et al. Italian Co-infection Study (ICOS) Group. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther 2005; 10:309-331.
11. Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18:F21-F25. Substudy from APRICOT addressing safety issues and clearly identifying risk factors associated with hepatic decompensation under PegIFN/ribavirin therapy in HIV/HCV-coinfected individuals.
12. Lafeuillade A, Hittinger G, Chapadau DS. Increased mitochondrial toxicity with ribavirin in HIV/HCV-coinfection. Lancet 2001; 357:280-281.
13. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, et al. Mitochondrial toxicity effects and ribavirin. Lancet 2001; 357:1803-1804.
14. Vogt MW, Hartson KL, Forman PA. Ribavirin antagonizes the effect of azidothymidin on HIV-replication. Science 1987; 325:1267-1279.
15. Fernandez-Larsson R, Patterson JL. Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase. Molecular Pharmacol 1990; 38:766-770.
16. Gries JM, Torriani FJ, Rodriguez-Torres M, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HCV/HIV coinfection: final results of a randomized clinical study. 11th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2004; San Francisco. Alexandria, Virginia: Foundation for Retrovirology and Human Health; 2004. Abstract 136LB.
17. Nunez M, Maida M, Berdun A, et al. Efficacy and safety of peginterferon-alpha2a plus ribavirin (PegIFN + RBV) for the treatment of hepatitis C in HIV co-infected patients: the PRESCO Trial. 44th ICAAC; 30 October-2 November 2004; Washington. Washington, DC: American Society for Microbiology; 2004. p. 463, V-1148.
18. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated interferon-α 2b + ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023-1028.
19. Voigt E, Schulz C, Klausen G, et al. for the KAAD study group. Pegylated interferon α-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. Infection 2005 [Epub ahead of print].
20. Zanini B, Puoti M, Quiros Roldan E, et al. The optimal duration of treatment for HIV-infected patients with chronic hepatitis C (CHC) and genotype 2 or 3 is 48 weeks: results of a randomized controlled trial. 3rd IAS Conference on HIV Pathogenesis and Treatment; 24-27 July 2005; Rio de Janeiro. International AIDS Society; 2005. MoPpLB0103.
21. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615-624. This is the first European consensus document on management of hepatitis B and C coinfection in HIV patients. It provides excellent guidance and is a great achievement addressing most relevant and often controversial questions around the care of this difficult-to-treat patient population.
22. Nelson M, Matthews G, Brook MG, Main J. BHIVA Coinfection Guideline Committee; British HIV Association. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005). HIV Med 2005; Suppl 2:96-106.
23. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS 2004; 18:1-12.
24. Gambotti L, Batisse D, Colin-de-Verdiere N, et al. Acute hepatitis C collaborating group. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill 2005; 10:115-117.
25. Browne R, Asboe D, Gilleece Y, et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? Sex Transm Infect 2004; 80:326-327.
26. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452-1457.
27. Vogel M, Bieniek B, Jessen H, et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat 2005; 12:207-211.
28. Vogel M, Dupke S, Baumgarten A, et al. HCV/RNA 4 weeks after interferon/ribavirin therapy predictive for end-of-treatment response in acute hepatitis C. 12th Conference on Retroviruses and Opportunistic Infections; 22-25 February 2005; Boston. Alexandria, Virginia: Foundation for Retrovirology and Human Health; 2005. Abstract 922.
29. Chaix ML, Serpaggi J, Batisse D, et al. Homosexually transmitted HCV acute infection related to a clustered genotype 4 HCV in HIV-1-infected men and inefficacy of early antiviral therapy. 12th Conference on Retroviruses and Opportunistic Infections; 22-25 February 2005; Boston. Alexandria, Virginia: Foundation for Retrovirology and Human Health; 2005. Abstract 122.
30. Nelson M, Gilleece Y, Browne R, et al. Is the treatment of acute hepatitis C in HIV-positive individuals effective? 3rd IAS Conference on HIV Pathogenesis and Treatment; 24-27 July 2005; Rio de Janeiro. International AIDS Society; 2005. TuPe1.1C10.
31. Sulkowski MS, Dieterich DT, Bini EJ, et al. for the HIV/HCV Coinfection Study Group. Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr 2005; 39:504-506. In anemic HCV-infected patients treated with ribavirin/interferon, epoetin alfa increases hemoglobin levels and maintains ribavirin dosing. Based on these results, epoetin alfa seems to be promising in the treatment of HCV treatment-related anemia.
32. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96:179-183.
33. Puoti M, Bruno R, Soriano V, et al. HIV HCC Cooperative Italian-Spanish Group. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18:2285-2293. Hepatocellular carcinoma in HIV-infected patients is mainly associated with underlying chronic hepatitis C and has a more aggressive clinical course.
34. Rockstroh JK, Spengler U. HIV and HCV co-infection. Lancet Inf Dis 2004; 4:437-444.
35. Miro JM, Montejo M, Rufi G, et al. Liver transplantation in patients with HIV infection: a reality in 2004. Enferm Infecc Microbiol Clin 2004; 22:529-538.
36. Ragni M, Belle S, Im K, et al. Survival in HIV infected liver transplant recipients. 10th Conference on Retroviruses and Opportunistic Infections; 10-15 February 2003; Boston. Alexandria, Virginia: Foundation for Retrovirology and Human Health; 2003. Abstract 155.
37. Vogel M, Voigt E, Schäfer N, et al. Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients - outcome of 7 patients from the Bonn cohort. Liver Transpl 2005 (in press).
38. Vogel M, Voigt E, Michelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004; 10:939-944. Under ritonavir-boosted HAART, cyclosporine A levels showed markedly altered absorption/elimination characteristics with more or less constant blood levels throughout the dosing interval and prolonged elimination half-lives up to 38 h. To obtain equivalent areas under the curve of cyclosporine A, daily doses were reduced to 5-20% of the individual standard doses given before initiation of ritonavir-boosted HAART. Because of the flat absorption/elimination profiles under ritonavir-boosted HAART cyclosporine A, dosing could be reliably monitored long term by measuring cyclosporine A trough levels.
39. Rockstroh JK, Theisen A, Kaiser R, et al. Antiretroviral triple therapy decreases HIV viral load and does not alter hepatitis C virus serum levels in HIV/HCV-coinfected hemophiliacs. AIDS 1998; 12:829-830.
40. Rutschmann OT, Negro F, Hirschel B, et al. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998; 177:783-785.
41. Benhamou Y, DeMartinio V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-287.